Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service
Open Access
- 1 April 2003
- journal article
- other
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 62 (4) , 350-352
- https://doi.org/10.1136/ard.62.4.350
Abstract
Objective: To identify the most common diseases and age of corticosteroid use in women over 50, dosage in last year, duration of oral corticosteroid use, prescription for fracture prevention (drug used), and referrals for bone densitometry. Methods: General practice records from 41 practices in Shropshire identified 62 230 women aged >50 from a population of 80 082. Data on fractures, duration of corticosteroid use, dose in the study year (1 April 1997–31 March 1998), use of fracture prevention therapy and bone densitometry were sampled from one out of three records. Results: 3.2% were prescribed corticosteroids; 633 patients investigated in detail aged 70.1 (SD 10.5) years, had been prescribed 1526 (SD 1727) mg prednisolone (median 1040 mg) for 3.31 (SD 3.20) years (median 2.0 years). Patients with asthma/lung disease, most common in the younger group, had the lowest annual corticosteroid use; patients with rheumatoid arthritis (RA), polymyalgia rheumatica/temporal arteritis (PMR/TA), who were more likely to be elderly, had the highest annual use. Between the age of 70 and 79 years patients with RA had significantly more hip fractures than the other groups, and corticosteroid prescribing was most common. Bisphosphonates or hormone replacement therapy were prescribed for 48% aged 50–59 years but only 32% at 70–79 years (pConclusions: The elderly had the most prescriptions for corticosteroid treatment but the fewest for effective fracture prevention therapy. Patients with RA, PMR/TA had the greatest corticosteroid dosage, for the longest time. Patients with RA sustained more hip fractures than other groups but were least likely to have effective fracture prevention therapy prescribed.Keywords
This publication has 15 references indexed in Scilit:
- Oral corticosteroids and fracture risk: relationship to daily and cumulative dosesRheumatology, 2000
- Effects of Risedronate Treatment on Bone Density and Vertebral Fracture in Patients on Corticosteroid TherapyCalcified Tissue International, 2000
- Use of oral corticosteroids in the United KingdomQJM: An International Journal of Medicine, 2000
- Risedronate therapy prevents corticosteroid-induced bone loss : A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyArthritis & Rheumatism, 1999
- Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention TrialJAMA, 1998
- Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced OsteoporosisNew England Journal of Medicine, 1997
- Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional studyBMJ, 1996
- Management of corticosteroid‐induced osteoporosisJournal of Internal Medicine, 1995
- Rheumatoid arthritis, corticosteroid therapy and hip fracture.Annals of the Rheumatic Diseases, 1995
- Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone lossJournal of Bone and Mineral Research, 1992